Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines

Annals of Surgical Oncology

Volumn 14, Issue 9, 2007, Pages 2678-2684

  Alam, Mahmood ^a   Wang, Jiang Huai ^a   Coffey, John Calvin ^a   Qadri, Syed Suhail ^a   O'Donnell, Aonghus ^a   Aherne, Thomas ^a   Redmond, Henry Paul ^a  

^a University College Cork   (Ireland)

Author keywords

Apoptosis; COX 2; Human lung cancer; NF B; P38 MAP kinase; Rofecoxib

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ROFECOXIB; SN 50;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; LACTONES; LUNG NEOPLASMS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; SIGNAL TRANSDUCTION; SULFONES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 34548564537     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9359-y     Document Type: Article

References (41)

1. National Cancer Registry. Cancer in Ireland, 1994-1998. Department of Health, Dublin, Ireland. 2004
2. Greenberg AK, Basu S, Hu J, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 2002;26:558-64
3. Qadri SSA, Wang JH, Redmond KC, O'Donnell AF, Aherne T, Redmond HP. The role of COX-2 inhibitors in lung cancer. Ann Thorac Surg 2002;74:1648-52
4. Qadri SSA, Wang JH, Coffey JC, et al. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg 2005;79:990-5
5. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004;31(2 Suppl 7):22-9
6. Harris RE, Beebe-Donk J, Doss H, Burr-Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005;13:559-83
7. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42
8. Ratnasinghe LD, Graubard BI, Kahle L, et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004;24(5B):3177-84
9. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40
10. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-22
11. Dai Y, Wang WH. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol 2006;12:2884-9
12. Hei TK. Cyclooxygenase-2 as a signaling molecule in radiation-induced bystander effect. Mol Carcinog 2006;45:455-60
13. Krysan K, Reckamp KL, Sharma S, Dubinett SM. The potential and rationale for COX-2 inhibitors in lung cancer (review). Anticancer Agents Med Chem 2006;6:209-20
14. Onguru O, Casey MB, Kajita S, et al. Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors (review). Endocr Pathol 2005;16:253-77
15. Telliez A, Furman C, Pommery N, Henichart JP. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 2006;6:187-208
16. Oshima M, Dinchuk JE, Kargman S, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9
17. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40
18. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase-2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30:73-81
19. Wolff H, Saukkonen K, Anttila A, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1999;58:4997-5001
20. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7
21. Ikezoe T, Yang Y, Saitoh T, et al. PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells. Int J Oncol 2006;29:453-61
22. Mascaux C, Martin B, Paesmans M, et al. Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 2006;95:139-45
23. Nakata H, Uemura Y, Kobayashi M, Harada R, Taguchi H. Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells. Cancer Sci 2003;94:173-80
24. Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 2002;6:838-44
25. Yao M, Kargman S, Lam CE, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-92
26. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175:8242-52
27. Chow LW, Loo WT, Toi M. Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother 2005;59(Suppl 2):S281-4
28. Klenke FM, Gebhard MM, Ewerbeck V, et al. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006;6:9
29. Wu YL, Fu SL, Zhang YP, et al. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother 2005;59(Suppl 2):S289-92
30. Yee KK, Soo KC, Olivo M. Anti-angiogenic effects of hypericin- photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. Int J Mol Med 2005;16:993-1002
31. Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48:1998-2002
32. Hawkey CJ, Fortun PJ. Cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2005;21:660-4
33. Lew JI, Guo Y, Kim RK, et al. Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive. J Gastrointest Surg 2002;6:563-8
34. Nelson NJ. Celecoxib shown effective in preventing colon polyps. J Natl Cancer Inst 2006;98:665-7
35. Wang JH, Doyle M, Manning BJ, et al. Induction of bacterial lipoprotein tolerance is associated with suppression of toll-like receptor 2 expression. J Biol Chem 2002;277:36068-75
36. Coffey JC, Wang JH, Bouchier-Hayes D, et al. The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. Ann Surg 2006;243:250-6
37. Coffey JC, Wang JH, Smith MJ, et al. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 2005;280:20968-77
38. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-31
39. Hida T, Kozaki KI, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-11
40. Qadri SS, Wang JH, Coffey JC, et al. Can surgery for cancer accelerate the progression of secondary tumors within residual minimal disease at both local and systemic levels? Ann Thorac Surg 2005;80:1046-50
41. Tsuji M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16